PROVECTUS BIOPHARMACEUTICALS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$5.51 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-26
- PROVECTUS BIOPHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$5.51M.
- PROVECTUS BIOPHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$4.76M.
- PROVECTUS BIOPHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$3.09M.
- PROVECTUS BIOPHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$3.55M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$5.51M 10-K · filed 2026-03-26 | |
| 2024-12-31 | -$4.76M 10-K · filed 2026-03-26 | |
| 2023-12-31 | -$3.09M 10-K · filed 2025-03-28 | -$3.12M 10-K · filed 2024-03-28 |
| 2022-12-31 | -$3.55M 10-K · filed 2024-03-28 | |
| 2021-12-31 | -$5.45M 10-K · filed 2023-03-30 | |
| 2020-12-31 | -$6.63M 10-K · filed 2022-03-29 | -$632.59K 10-K · filed 2021-03-02 |
| 2019-12-31 | -$6.98M 10-K · filed 2021-03-02 | |
| 2018-12-31 | -$7.95M 10-K · filed 2020-03-05 | |
| 2017-12-31 | -$13.40M 10-K · filed 2019-03-07 |